KR20160061352A - 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 - Google Patents

벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20160061352A
KR20160061352A KR1020167009675A KR20167009675A KR20160061352A KR 20160061352 A KR20160061352 A KR 20160061352A KR 1020167009675 A KR1020167009675 A KR 1020167009675A KR 20167009675 A KR20167009675 A KR 20167009675A KR 20160061352 A KR20160061352 A KR 20160061352A
Authority
KR
South Korea
Prior art keywords
patient
copd
antigen
binding fragment
fev
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167009675A
Other languages
English (en)
Korean (ko)
Inventor
데르 멀리 르네 반
크리스틴 워드
위발도 마틴
로린 로스코스
빙 왕
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20160061352A publication Critical patent/KR20160061352A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167009675A 2013-10-15 2014-10-14 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 Ceased KR20160061352A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
KR20160061352A true KR20160061352A (ko) 2016-05-31

Family

ID=52809872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009675A Ceased KR20160061352A (ko) 2013-10-15 2014-10-14 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법

Country Status (12)

Country Link
US (4) US20150104447A1 (cg-RX-API-DMAC7.html)
EP (2) EP3485902A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016534996A (cg-RX-API-DMAC7.html)
KR (1) KR20160061352A (cg-RX-API-DMAC7.html)
CN (2) CN105636607A (cg-RX-API-DMAC7.html)
AU (2) AU2014334563A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016008082A2 (cg-RX-API-DMAC7.html)
CA (1) CA2925402A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016004329A (cg-RX-API-DMAC7.html)
RU (1) RU2706729C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201807318RA (cg-RX-API-DMAC7.html)
WO (1) WO2015057668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Fc受容体結合が変更された非対称抗体および使用方法
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
JP6895884B2 (ja) 2015-06-01 2021-06-30 国立大学法人富山大学 肺高血圧症の治療薬及び治療方法
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
US20210230265A1 (en) * 2019-12-06 2021-07-29 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素-5受体α链的抗体
EP2278003B2 (en) * 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) * 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
PT2068927E (pt) * 2007-05-14 2016-02-10 Medimmune Llc Métodos para reduzir os níveis de eosinófilos
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
US20130281876A1 (en) * 2010-10-15 2013-10-24 Medimmune Limited Therapies for improving pulmonary function
TWI666447B (zh) * 2010-12-16 2019-07-21 建南德克公司 關於th2抑制作用之診斷及治療
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
RU2014122189A (ru) * 2011-11-01 2015-12-10 МЕДИММЬЮН, ЭлЭлСи Способы снижения частоты и тяжести острых приступов астмы
TR201903312T4 (tr) * 2013-08-12 2019-04-22 Astrazeneca Ab Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
PL3520811T3 (pl) * 2013-08-12 2021-08-02 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
KR102337601B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법

Also Published As

Publication number Publication date
JP2021107421A (ja) 2021-07-29
SG10201807318RA (en) 2018-09-27
JP2019203009A (ja) 2019-11-28
EP3485902A1 (en) 2019-05-22
JP2016534996A (ja) 2016-11-10
EP3057609A4 (en) 2017-03-22
CA2925402A1 (en) 2015-04-23
CN105636607A (zh) 2016-06-01
AU2020202333A1 (en) 2020-04-23
WO2015057668A1 (en) 2015-04-23
RU2016118425A (ru) 2017-11-21
CN113230399A (zh) 2021-08-10
US20200123262A1 (en) 2020-04-23
RU2016118425A3 (cg-RX-API-DMAC7.html) 2018-07-19
MX2016004329A (es) 2016-11-10
RU2706729C2 (ru) 2019-11-20
SG11201601807XA (en) 2016-04-28
AU2014334563A1 (en) 2016-04-07
US20150104447A1 (en) 2015-04-16
EP3057609A1 (en) 2016-08-24
US20180291108A1 (en) 2018-10-11
MX2019013468A (es) 2020-02-12
JP6870037B2 (ja) 2021-05-12
BR112016008082A2 (pt) 2017-10-17
US20170107291A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
JP6870037B2 (ja) ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
Suzukawa et al. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab
Shioya et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma
KR20160042123A (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
Agbetile et al. New therapies and management strategies in the treatment of asthma: patient-focused developments
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
Kermode et al. The effect of airway remodelling on airway hyper-responsiveness in asthma
Saji et al. Efficacy of long-term omalizumab therapy in patients with severe asthma
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20230348606A1 (en) Methods for treating severe asthma in patients with nasal polyposis
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
Davies The effect of Obstructive Sleep Apnoea (OSA) on health outcomes in patients with asthma: epidemiology, impact on asthma control, and effect of treatment using Continuous Positive Airway Pressure (CPAP)
JP2025527762A (ja) 抗インターロイキン-33抗体を用いた喘息の治療

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170206

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210216

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20211024

Patent event code: PE09021S02D

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20220727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211024

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20210216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20220727

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20220224

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20210614